27th Jun 2023 12:13
N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Says it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council. Professor Chengzhong Yu, senior group leader at the Australian Institute for Bioengineering & Nanotechnology, has been awarded an AUD402,115 grant - around GBP211,366 - to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid therapies.
Chief Executive Officer Nigel Theobald says: "We are pleased to continue our close collaboration with Professor Yu and work on new ways to build on the performance of our Nuvec nanoparticle together."
Current stock price: 1.65 pence
12-month change: down 30%
By Holly Beveridge, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
N4 Pharma Plc